Key Points
- Insider sale: Brian Adams sold 6,371 Kymera Therapeutics shares for approximately $744,324 to cover tax withholding related to vested equity awards, reducing his ownership by 11.25%.
- Quarterly performance: Kymera reported a quarterly loss of $0.62 per share, better than analysts’ expected $0.71 loss, while revenue surged 465.2% year over year to $65 million.
- Analyst sentiment: Wall Street maintains a “Moderate Buy” consensus with a $128.70 price target; major institutions, including BlackRock and Merck, recently acquired stakes in the company.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) insider Brian Adams sold 6,371 shares of the firm's stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider owned 50,254 shares of the company's stock, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kymera Therapeutics Trading Up 0.1%
Shares of KYMR opened at $117.39 on Friday. The company's 50-day moving average price is $114.16 and its 200 day moving average price is $94.90. Kymera Therapeutics, Inc. has a 12-month low of $42.22 and a 12-month high of $130.05. The firm has a market cap of $9.76 billion, a P/E ratio of -36.23 and a beta of 1.96.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The company had revenue of $65.00 million for the quarter, compared to analysts' expectations of $32.78 million. During the same period in the prior year, the firm earned ($0.95) earnings per share. The firm's revenue was up 465.2% compared to the same quarter last year. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current year.
Institutional Investors Weigh In On Kymera Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Merck & Co. Inc. acquired a new stake in shares of Kymera Therapeutics during the second quarter worth about $88,544,161. Deutsche Bank AG purchased a new stake in shares of Kymera Therapeutics in the second quarter valued at about $12,161,000. Eagle Health Investments LP acquired a new stake in Kymera Therapeutics during the 2nd quarter worth approximately $19,052,000. BlackRock Inc. purchased a new stake in shares of Kymera Therapeutics during the second quarter worth approximately $635,067,000. Finally, State of New Jersey Common Pension Fund D acquired a new stake in shares of Kymera Therapeutics during the fourth quarter worth $2,610,000.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on KYMR shares. Wells Fargo & Company upped their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an "overweight" rating in a report on Thursday, August 27th. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a research note on Monday, June 8th. Canaccord Genuity Group lifted their price objective on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a "buy" rating in a research report on Friday, June 26th. Bank of America lifted their price target on Kymera Therapeutics from $110.00 to $125.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Finally, Citigroup reaffirmed a "buy" rating on shares of Kymera Therapeutics in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $128.70.
View Our Latest Research Report on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
